PharmaEssentia (6446) investor relations material

Executive summary

• Q2 2026 revenue reached NT$6.86 billion, marking a 90% year-over-year increase, with monthly revenue exceeding NT$2 billion for three consecutive months.

• Net operating income for Q2 2026 was NT$3.16 billion, up 188% YoY, and net income was NT$2.53 billion, up 204% YoY.

• H1 2026 revenue grew nearly 75% YoY to NT$11.98 billion, with net income for H1 at NT$4.68 billion, up 123% YoY.

• Gross margin improved to 94.2% in Q2 2026, up 6.7 percentage points YoY, and operating margin rose to 36.9%, up 13.8 percentage points.

• EPS for Q2 2026 reached a record NT$6.13, up 202% YoY.

Outlook and guidance

• Continued global expansion of ROPEG (Ropeginterferon alfa-2b) with regulatory approvals in Canada, and anticipated approvals in Japan and the U.S. for ET indication in August 2026.

• Early-stage pipeline in oncology and immunology expected to drive future growth, with four products targeted to enter Phase 1 clinical trials by 2027.

• Strategic focus on expanding PEG platform applications and broadening ROPEG’s therapeutic use in hematologic and solid tumor indications.

Segment performance

• Commercial product line led by ROPEG, approved for PV in 50 countries, with expanding patient access and strong growth in the U.S., EU, and Asia.

• R&D pipeline includes ongoing Phase 3 trials for early/pre-fibrotic PMF and new indications in CML, HCC, AML, CTCL, and CMML.